Iñaki Lete
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Iñaki Lete has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
C. Coll
6 shared publicationsI. Serrano
6 shared publicationsJ. Martínez-Salmeán
5 shared publications- José Luis Dueñas
Obstetrics and Gynecology Department, Virgen Macarena University Hospital, Medical School, University of Seville, Seville, Spain
5 shared publications R. Bermejo
5 shared publicationsEzequiel Pérez-Campos
Service of Gynecology, Hospital de Requena, Valencia, Spain
4 shared publications
Latest Publications
- 18 June 2015
- Published by Springer Nature in PharmacoEconomics Spanish Research Articles
- Vol. 12 (3) , 105-114
Evaluación económica de los tratamientos orales para el sangrado menstrual abundante en España
- 18 June 2015
- Published by Springer Nature in PharmacoEconomics Spanish Research Articles
- Vol. 12 (3) , 105-114
Evaluación económica de los tratamientos orales para el sangrado menstrual abundante en España
- 1 May 2012
- Published by SAGE Publications in Journal of Women's Health
- Vol. 21 (5) , 490-495
Continuation Rate of Combined Hormonal Contraception: A Prospective Multicenter Study
Data from clinical trials regarding continuation of use and contraceptive efficacy do not always apply to the general public. Therefore, a study among typical users was conducted to assess the continuation rate at the end of 12 cycles of combined hormonal contraceptive methods, reasons for discontinuation, and the Pearl index. Prospective, observational, and multicenter study of 3443 women aged 18 to 49 years starting one of the three combined hormonal contraception methods available in Spain (the vaginal ring, the contraceptive pill, and the transdermal skin patch). The study population (intention-to-treat analysis) included 3443 women, of whom 45.4% were included in the vaginal ring group, 42.6% the pill group, and 12.1% the skin patch group. The continuation rate at 12 cycles was 45.9% for the pill, 42.3% for the vaginal ring, and 26.0% for the skin patch. The Pearl index was 0.61 (95% confidence interval [CI] 0-1.2) for the pill, 0.61 (95% CI 0-1.1) for the vaginal ring, and 2.34 (95% CI 0.3-9) for the skin patch (p<0.001). At 12 cycles, the vaginal ring and the pill showed similar continuation rates and effectiveness, which were significantly higher than the skin patch.
- 1 May 2012
- Published by SAGE Publications in Journal of Women's Health
- Vol. 21 (5) , 490-495
Continuation Rate of Combined Hormonal Contraception: A Prospective Multicenter Study
Data from clinical trials regarding continuation of use and contraceptive efficacy do not always apply to the general public. Therefore, a study among typical users was conducted to assess the continuation rate at the end of 12 cycles of combined hormonal contraceptive methods, reasons for discontinuation, and the Pearl index. Prospective, observational, and multicenter study of 3443 women aged 18 to 49 years starting one of the three combined hormonal contraception methods available in Spain (the vaginal ring, the contraceptive pill, and the transdermal skin patch). The study population (intention-to-treat analysis) included 3443 women, of whom 45.4% were included in the vaginal ring group, 42.6% the pill group, and 12.1% the skin patch group. The continuation rate at 12 cycles was 45.9% for the pill, 42.3% for the vaginal ring, and 26.0% for the skin patch. The Pearl index was 0.61 (95% confidence interval [CI] 0-1.2) for the pill, 0.61 (95% CI 0-1.1) for the vaginal ring, and 2.34 (95% CI 0.3-9) for the skin patch (p<0.001). At 12 cycles, the vaginal ring and the pill showed similar continuation rates and effectiveness, which were significantly higher than the skin patch.
- Open Access
- 1 January 2012
- Published by SAGE Publications in Clinical Medicine Insights: Women's Health
- Vol. 5, CMWH.S9934
Hormonal Contraception and Diabetes
Women with gestational diabetes mellitus are at increased risk for developing diabetes mellitus (DM), mainly type 2 DM, as well as metabolic syndrome. The presence of subsequent pregnancies increases the risk. In addition, pregnancy in patients with type 1 and type 2 DM also elevates the risk of morbidity and mortality for both mothers and offspring. Thus, all women with pre-existing type 1 or type 2 DM should receive preconception care to optimize glycemic control (HbA1c ≤ 6%). In those cases with macrovascular or microvascular complications, family planning is even more important in order to avoid the risk of aggravation of such complications associated with a new pregnancy. The present review analyzes the metabolic and cardiovascular repercussions of hormone contraception in non-diabetic women as well as in type 1 and type 2 DM patients with and without macrovascular and microvascular complications. Finally, the recommendations pertaining to hormonal contraceptive methods for women with diabetes are summarized.
- 1 January 2012
- Published by SAGE Publications in Clinical Medicine Insights: Women's Health
- Vol. 5, CMWH.S9934
Open AccessHormonal Contraception and Diabetes
Women with gestational diabetes mellitus are at increased risk for developing diabetes mellitus (DM), mainly type 2 DM, as well as metabolic syndrome. The presence of subsequent pregnancies increases the risk. In addition, pregnancy in patients with type 1 and type 2 DM also elevates the risk of morbidity and mortality for both mothers and offspring. Thus, all women with pre-existing type 1 or type 2 DM should receive preconception care to optimize glycemic control (HbA1c ≤ 6%). In those cases with macrovascular or microvascular complications, family planning is even more important in order to avoid the risk of aggravation of such complications associated with a new pregnancy. The present review analyzes the metabolic and cardiovascular repercussions of hormone contraception in non-diabetic women as well as in type 1 and type 2 DM patients with and without macrovascular and microvascular complications. Finally, the recommendations pertaining to hormonal contraceptive methods for women with diabetes are summarized.
- Open Access
- 1 January 2011
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 154 (1) , 71-80
Economic evaluation of the levonorgestrel-releasing intrauterine system for the treatment of dysfunctional uterine bleeding in Spain
- 1 January 2011
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 154 (1) , 71-80
Open AccessEconomic evaluation of the levonorgestrel-releasing intrauterine system for the treatment of dysfunctional uterine bleeding in Spain
- 31 December 2009
- Published by Elsevier in Medicina de Familia. SEMERGEN
- Vol. 35 (10) , 505-510
Efectos beneficiosos no anticonceptivos de la píldora anticonceptiva
- 31 December 2009
- Published by Elsevier in Medicina de Familia. SEMERGEN
- Vol. 35 (10) , 505-510
Efectos beneficiosos no anticonceptivos de la píldora anticonceptiva
- 30 November 2008
- Published by Elsevier in Value in Health
- Vol. 11 (6) , A423
PIH9 COST-EFFECTIVENESS OF LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS) FOR THE TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING (DUB) IN SPAIN
- 30 November 2008
- Published by Elsevier in Value in Health
- Vol. 11 (6) , A423
PIH9 COST-EFFECTIVENESS OF LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS) FOR THE TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING (DUB) IN SPAIN
- 1 April 2008
- Published by Elsevier in Contraception
- Vol. 77 (4) , 276-282
Self-described impact of noncompliance among users of a combined hormonal contraceptive method
- 1 April 2008
- Published by Elsevier in Contraception
- Vol. 77 (4) , 276-282
Self-described impact of noncompliance among users of a combined hormonal contraceptive method